							Shee	t 1 of 2
U.S. Department of Commerce, Patent and Trademar					Atty Docket No.		Serial No.	
₩3442-2						-2 DIV	To Be Assign	
LIST OF REFERENCES CITED BY APPLICANTS icants								2.5
(Use several sheets if necessary) .her et al.								- <u>:8</u>
	ıling Date						Group 65	
	Herewith						To Be Assigned	
			U.S. P	atent Documents				
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	1		Foreign	Patent Documents		<u>L</u>	<u> </u>	
							Translation	
		Document	Date	Country	Class	Subclass	Yes	No
SIM	1	WO 97 35989	2 Oct 1997	PCT				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
554	2	Beavo, J.A., "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", Physiological Reviews, 75: 725-748 (1995)					ations	
	3	Verghese, M.W. et al., "Regulation of Distinct Cyclic AMP-Specific Phosphodiesterase (Phosphodiesterase Type 4) Isozymes in Human Monocytic Cells", Mol. Pharmacol., 47: 1164-1171 (1995)						
	4	Angel, J.B. et al., "Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication", AIDS, 9: 1137-1144 (1995)						
	5	Sommer, N. et al., "The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis", <u>Nat. Med.</u> , 1: 244-248 (1995)						
	6	Sasaki, H. et al., "Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperido", Eur. J. Pharmacol. , 282: 71-76 (1995)						
	7	Banner, K.H. and C.P. Page, "Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma", Eur. Respir. J. , 8: 996-1000 (1995)						
	8	Bang, YJ. et al., "Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP", Proc. Natl. Acad. Sci. USA, 91: 5330-5334 (1994)						
	9	Matousovic, K. et al., "Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells", J. Clin. Invest., 96: 401-410 (1995)						
V	10	Joulain, C. et al., "Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation", <u>J. Lipid Mediat. Cell Signal.</u> , 11: 63-79 (1995)						
Examiner	K,	Date Considered & UNOZ						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.								



09/802 141

PF-0442-2 DIV Sheet 2 of 2

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		racing mather, field, bate, refullent rages, Etc.)
DH	11	Deonarain M.P. and A. Epenetos, "Targeting enzymes for cancer therapy: old enzymes in new roles", <u>Br. J. Cancer</u> , 70: 786-794 (1994)
	12	Davis, R. and Y. Qiu, (Direct Submission), GenBank Sequence Database (Accession X55167, S70588, S70600, X55247), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894 (GI 7897; GI 829179)
	13	Qiu, Y. et al., "Characterization of the Memory Gene Dunce of <i>Drosophila melanogaster"</i> , <u>J. Mol. Biol.</u> , 222: 553-565 (1991), (GI 7897; GI 829179)
	14	Segel, I.H., <u>ENZYME KINETICS</u> , John Wiley and Sons, New York, NY, pp. 214-245 (1995)
	14	National Cancer Institute, Cancer Genome Anatomy Project: "Homo sapiens cDNA clone IMAGE: 900018 similar to WP:R153.1 CE02038 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE," (Acc. No. AA502909) (GI 2237876), 4 July 1997.
	15	Fisher, D.A. et al., "Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase," <u>J. Biol. Chem.</u> , 273(25):15559-15564 (1998).
Examiner		Date Considered \$ 178 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.